The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 05, 2015

Filed:

Aug. 05, 2011
Applicants:

Alexis Kays Leonard, Maple Valley, WA (US);

Joshua Orion Sestak, Lawrence, KS (US);

Henry R. Costantino, Woodinville, WA (US);

Anthony P. Sileno, Mendham, NJ (US);

Lalit Raj Peddakota, San Diego, CA (US);

Kayvon Emile Sharghi, Chevy Chase, MD (US);

Garland M. Bellamy, Santa Fe, NM (US);

Jason Philip Gesty, Seattle, WA (US);

Steven C. Quay, Seattle, WA (US);

Inventors:

Alexis Kays Leonard, Maple Valley, WA (US);

Joshua Orion Sestak, Lawrence, KS (US);

Henry R. Costantino, Woodinville, WA (US);

Anthony P. Sileno, Mendham, NJ (US);

Lalit Raj Peddakota, San Diego, CA (US);

Kayvon Emile Sharghi, Chevy Chase, MD (US);

Garland M. Bellamy, Santa Fe, NM (US);

Jason Philip Gesty, Seattle, WA (US);

Steven C. Quay, Seattle, WA (US);

Assignee:

Retrophin, Inc., San Diego, CA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/11 (2006.01); A61P 5/10 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01); A61K 31/337 (2006.01); A61K 9/08 (2006.01);
U.S. Cl.
CPC ...
A61K 9/0043 (2013.01); A61K 45/06 (2013.01); A61K 31/337 (2013.01); A61K 9/08 (2013.01);
Abstract

Methods and compositions containing oxytocin or an oxytocin analog, such as carbetocin, are provided for the prevention and treatment of autism spectrum disorders, related disorders and symptoms of such disorders. The methods and compositions of this disclosure are effective in the treatment of social withdrawal, eye contact avoidance, repetitive behaviors, anxiety, attention deficit, hyperactivity, depression, loss of speech, verbal communication difficulties, aversion to touch, visual difficulties, comprehension difficulties, and sound and light sensitivity. Additional compositions and methods are provided which employ oxytocin or an oxytocin analog in combination with a secondary or adjunctive therapeutic agent to yield more effective treatment tools against autism spectrum disorders and related disorders.


Find Patent Forward Citations

Loading…